Tscan Therapeutics Inc
(TCRX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -48,625 | -34,425 | -18,586 | -7,912 | -26,127 |
| Depreciation Amortization | 3,328 | 2,186 | 1,130 | 469 | 1,230 |
| Accounts payable and accrued liabilities | 10 | 2,472 | 1,593 | 162 | 1,127 |
| Other Working Capital | -5,896 | -3,790 | -4,048 | -2,858 | 21,357 |
| Other Operating Activity | 2,506 | -740 | -746 | 182 | -610 |
| Operating Cash Flow | $-48,677 | $-34,297 | $-20,657 | $-9,957 | $-3,023 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -9,941 | -7,730 | -6,877 | -2,959 | -4,238 |
| Investing Cash Flow | $-9,941 | $-7,730 | $-6,877 | $-2,959 | $-4,238 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 89,938 | 89,818 | 170 | 108 | 288 |
| Other Financing Activity | 99,730 | 99,730 | 98,770 | 99,518 | 0 |
| Financing Cash Flow | $189,668 | $189,548 | $98,940 | $99,626 | $288 |
| Beginning Cash Position | 35,386 | 35,386 | 35,386 | 35,386 | 42,359 |
| End Cash Position | 166,436 | 182,907 | 106,792 | 122,096 | 35,386 |
| Net Cash Flow | $131,050 | $147,521 | $71,406 | $86,710 | $-6,973 |
| Free Cash Flow | |||||
| Operating Cash Flow | -48,677 | -34,297 | -20,657 | -9,957 | -3,023 |
| Capital Expenditure | -9,941 | -7,730 | -6,877 | -2,959 | -4,238 |
| Free Cash Flow | -58,618 | -42,027 | -27,534 | -12,916 | -7,261 |